In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks Jim Cramer recently talked about. Jim Cramer, the host of Mad Money, has been ...
In the last three months, 6 analysts have published ratings on Pfizer PFE, offering a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings ...
Pfizer (NYSE:PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to physicians to induce prescriptions for its migraine drug Nurtec ODT. The U.S ...
Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares closed yesterday at $26.01. According to ...
In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other dividend stocks. Dividend stocks, while popular among investors, have been underperforming for ...
In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE)) stands against other undervalued defensive stocks for 2025. The consumer defensive sector covers products that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback